Dec 10, 2024
Haitham Ayad, CEO of SPIMA Therapeutics, has secured a global licensing agreement for its lead peptide-based immunotherapy candidate, which targets the Myddosome complex involved in inflammation. This approach aims to target undruggable protein-protein interactions, leveraging the advantages of peptides over small...
Dec 10, 2024
Haitham Ayad, CEO of SPIMA Therapeutics, has secured a global licensing agreement for its lead peptide-based immunotherapy candidate, which targets the Myddosome complex involved in inflammation. This approach aims to target undruggable protein-protein interactions, leveraging the advantages of peptides over small...
Sep 12, 2023
David Esposito, President and CEO of ONL Therapeutics, is focused on back-of-the-eye diseases such as open-angle glaucoma, dry age-related macular degeneration, and retinal detachment. Their drug ONL1204 targets retina cells to block the Fas receptor to reduce damage to the eye. This small peptide is delivered via an...
Sep 12, 2023
David Esposito, President and CEO of ONL Therapeutics, is focused on back-of-the-eye diseases such as open-angle glaucoma, dry age-related macular degeneration, and retinal detachment. Their drug ONL1204 targets retina cells to block the Fas receptor to reduce damage to the eye. This small peptide is delivered via an...
Dec 27, 2022
Dr. Mark Sumeray is the Chief Medical Officer of Amolyt Pharma, focusing on rare diseases that affect the endocrine system, the hormonal system that regulates essential body functions. Despite the surgeon's best efforts, the parathyroid glands may be damaged or removed when operating on the thyroid gland creating...